The magnitude of response to NAC varies significantly according to BC subtype, and, hormone receptor positive, HER2-negative BC are less likely to respond to neoadjuvant chemotherapy than other biologic subtypes (Figure 2) [4]. Here, ERBB2 is linked to breast cancer.